about
Psychological interventions for people with hemophiliaMusculoskeletal complications of haematological diseaseIL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophiliaPhysical and psychosocial challenges in adult hemophilia patients with inhibitors.Recombinant FIXFc: a novel therapy for the royal disease?Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX.Nuclear factor (NF)-κB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia.Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.Treatment of hemophilia: a review of current advances and ongoing issuesClinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A.Challenges and successes in the treatment of hemophilia: the story of a patient with severe hemophilia A and high-titer inhibitors.Pathophysiology of Hemophilic Arthropathy.Modern management of haemophilic arthropathy.Secondary prophylaxis in adolescent and adult haemophiliacs.Physiopathology of haemophilic arthropathy.Clinical use of factor VIII and factor IX concentratesBeyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors.Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia BWFH State-of-the-Art Session on Therapeutic Gene Transfer Buenos Aires, Argentina.Novel drugs to treat hemophilia.Home treatment of haemophilia patients with inhibitors.Sexual evaluation and treatment of ageing males with haemophilia.Role of exercise and physical activity on haemophilic arthropathy, fall prevention and osteoporosis.Pharmacotherapy of haemophilia A.The role of ultrasonography in the diagnosis of the musculo-skeletal problems of haemophilia.Hemophilia and prophylaxis.The burden of bleeding in haemophilia: is one bleed too many?Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Optimal management of hemophilic arthropathy and hematomasDifferentiating between signs of intra-articular joint bleeding and chronic arthropathy in haemophilia: a narrative review of the literature.New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins.Optimising musculoskeletal care for patients with haemophilia.Prevalence and impact of obesity in people with haemophilia: Review of literature and expert discussion around implementing weight management guidelines.Surgical procedures in patients with haemophilic arthropathy of the ankle.The Role of Angiogenesis in Haemophilic Arthropathy: Where Do We Stand and Where Are We Going?The ICF (International Classification of Functioning, Disability and Health) developed by the WHO for measuring function in hemophilia.Using mouse models to investigate the pathophysiology, treatment, and prevention of post-traumatic osteoarthritis.Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models.Comparative burden of arthropathy in mild haemophilia: a register-based study in Sweden.Clinical outcomes and patient satisfaction following total joint replacement in haemophilia--23-year experience in knees, hips and elbows.Surgical complications in a hemophilia patient with factor VIII inhibitor and their endovascular management.
P2860
Q24197868-0FBEC14E-D71D-4BC6-93BC-5A7244444C55Q26786755-7083C008-8B26-49F7-984B-7F5F4AE96CAEQ30439206-C9C5B7D5-3ADC-4478-B76A-E30EDC9621A4Q33968730-40FA7F0C-558E-40DE-AFB4-5FDCFEF3C939Q33968782-8F0062E8-2C24-45D9-9289-912199B8CD62Q34197559-68273A46-8E39-4EB1-AE0D-C39FE5AF4748Q34508572-01DD7ACD-045F-412B-94DB-5A4FCA7F7E8CQ35311771-DA46D78C-6027-486B-A740-E157904A14FDQ35683781-6271424A-4E06-4A05-90A7-733B3797B20BQ35818302-249427D8-2D7B-4026-ADA3-D57283A45946Q36019034-416D5D98-65D9-49B0-B947-B00041225619Q36414215-E8750EE8-8A2D-4989-A05B-15F290FDE1E8Q36753030-00F7D2F5-A880-4CD3-BA3D-22A8DF42291EQ37119647-3D82A6BC-590A-4E80-AE3B-3EEBFE60D9FEQ37169661-6F162A04-B7A1-44EE-8E61-D4FD89DB64F7Q37370356-81FEC5FB-3289-458E-9F3B-F5C61DC8FD72Q37609087-0F5F2E8B-8D14-422D-B848-1DD7B92BEBB4Q37768868-419725C0-3053-4B22-985E-77F1C0033D48Q37775029-0C9B787A-9BE8-4218-8473-D5C29531B1DFQ37808746-CD4E2C00-505B-476C-A3DB-C458D09DBDB7Q37849338-9564B459-CF16-47BD-81DE-DFBB0A4A3CE3Q37857364-CF3B73DF-1A4E-4482-A148-342989427B66Q37891089-4DA68823-6477-441F-AFB0-6F6B5DF79FDAQ37951699-662A59ED-17A4-4A34-BCAB-B33029A952F8Q38056467-DCED4EF3-C7A9-45BE-ACC2-F15EEF4978CAQ38182702-31972DA2-5224-45DA-A43E-CD0A67AE0980Q38227605-9203E396-ACA5-4564-BB62-E059C30CD57FQ38266031-BCD0B1E8-F3FD-46F7-A2D8-FD4702E3E9ABQ38411798-346DA55B-DE94-4861-84EF-542F21FBE31FQ38574414-0684C0CD-1D4D-443F-8A0D-AD3E468D5326Q38672487-62A9F30C-0A08-4E1E-AB49-44B119C672A1Q38715839-27114C57-4002-4EA4-A4C1-A9A35819BE3BQ38793760-881F9D4B-32EF-4227-A67A-F2FB30A7091BQ38841195-5D704ADE-C220-4A91-B9A6-E148388495ADQ38842446-0FDBC26E-821D-4523-9FAA-C3109AA42D57Q38867664-8847934C-264D-4F91-AF66-0DD5777CC5FEQ38937408-17B54645-A9C5-4B85-9567-D738C086BB77Q38982572-F99DD5A2-A092-412E-8E18-71239302C2E2Q39264672-7CFC723B-32DA-45AF-B373-417654910E00Q39843451-1C3D59A7-C8DF-486F-AABF-E8901478BDF9
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Pathogenesis of haemophilic arthropathy.
@ast
Pathogenesis of haemophilic arthropathy.
@en
type
label
Pathogenesis of haemophilic arthropathy.
@ast
Pathogenesis of haemophilic arthropathy.
@en
prefLabel
Pathogenesis of haemophilic arthropathy.
@ast
Pathogenesis of haemophilic arthropathy.
@en
P2860
P1433
P1476
Pathogenesis of haemophilic arthropathy.
@en
P2093
Lafeber FP
Roosendaal G
P2860
P304
P356
10.1111/J.1365-2516.2006.01268.X
P478
12 Suppl 3
P577
2006-07-01T00:00:00Z